Observational studyCancer reports (Hoboken, N.J.)2025
Diagnostic Accuracy of Procalcitonin in the Diagnosis of Sepsis in Cancer Patients Hospitalized for Infection.
Observational study in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic Accuracy of Procalcitonin in the Diagnosis of Sepsis in Cancer Patients Hospitalized for Infection.Cancer reports (Hoboken, N.J.) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesSepsis is defined as a life-threatening, dysfunctional body-response to infection. Procalcitonin (PCT) is considered a marker of sepsis due to bacterial infections and it has been extensively used as a guide to antimicrobial management in the general population. The clinical role of PCT in cancer patients admitted to the Emergency Department (ED) for infection is still little researched.
methodsA prospective observational study enrolling all adult patients hospitalized for infection referred to the ED of IRCCS Azienda Ospedaliero-Universitaria di Bologna between February 1st, 2023 and July 31st, 2023 was conducted. The primary endpoint was to evaluate the accuracy of PCT in the diagnosis of sepsis (defined according to the latest guidelines) in patients with cancer in comparison to non-cancer patients.
results1041 out of 1125 eligible patients were enrolled (559 males and 482 females), out of whom 289 (27.8%) had active cancer. PCT levels differed between cancer and non-cancer patients (1 ng/mL with IQR 5.85 vs. 0.6 ng/mL with IQR 2.7; p < 0.001). The AUROC of PCT for the diagnosis of sepsis in the entire enrolled population was 0.717 (95% CI 0.683-0.745), whereas it was 0.655 (95% CI 0.592-0.718) in cancer patients and 0.743 (95% CI 0.708-0.778) in non-cancer patients (p = 0.016). A PCT cut-off of 0.5 ng/mL (PCT ≥ 0.5 ng/mL) confirmed its accuracy for predicting sepsis in non-cancer patients (sensitivity 71.5%, specificity 64.1%) but the specificity fell to 44.7% in cancer patients, although sensitivity remained good (sensitivity 78.9%). Conversely, a higher PCT cut-off of 1 ng/mL, as the most accurate threshold identified in the present study in the cancer population, showed a sensitivity of 66.9% and specificity of 61.2% in predicting sepsis in cancer patients.
conclusionOur study confirms the clinical role of PCT as a part of the diagnostic algorithm for sepsis but its diagnostic role is sub optimal in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.